StocksMedium•5 October 2026•
1 min read
Vaxcyte Stock Surges 57% on Positive Vaccine Trial Results Targeting Pfizer and Merck
Key Facts
1Vaxcyte shares surged 57% following positive trial results for its lead vaccine candidate, VAX-31.
2Jefferies analysts expect the new vaccine to capture a significant share of a market valued between $3 billion and $6 billion.
Vaxcyte shares surged 57% following positive trial results for its lead vaccine candidate, VAX-31. Barron's reported that the candidate successfully met primary endpoints in clinical studies, signaling that Vaxcyte can effectively compete with established pneumococcal vaccines from Pfizer and Merck.
Jefferies analysts expect the new vaccine to capture a significant share of a market valued between $3 billion and $6 billion. Regarding related equities, PCVX closed at $56.48 on October 2, 2026, while PFE closed at $27.80 and MRK closed at $144.30 on the same date.